Association of Serum Asprosin with the Risk Assessment of Diabetic Retinopathy
Association of Serum Asprosin with the Risk Assessment
DOI:
https://doi.org/10.54393/pjhs.v6i7.3116Keywords:
Diabetic Retinopathy, Asprosin, Diabetes, SerumAbstract
Diabetic retinopathy (DR) is a microvascular complication of uncontrolled diabetes, resulting from impaired retinal blood circulation. Asprosin, a recently identified adipokine, exacerbates this condition by inducing inflammatory cytokines that enhance retinal inflammation and vascular permeability. Objectives: To investigate the association of serum Asprosin levels with the progression of diabetic retinopathy and its potential role as a biomarker for early diagnosis and disease monitoring. Methods: This cross-sectional analytical study was conducted from January to December 2023, involving 255 participants divided into three groups: diabetics with no retinopathy, diabetics with retinopathy, and non-diabetic controls (85 each). Serum Asprosin, fasting glucose, insulin, lipid profiles, and other relevant clinical features were evaluated. Statistical analyses were conducted using SPSS version 26, including One-Way ANOVA, the Bonferroni test, and Pearson’s correlation. Results: The group with retinopathy showed the highest levels of Asprosin, insulin, fasting glucose, triglycerides, and LDL, while HDL was lowest in this group. The diabetic group showed intermediate levels, and controls showed the lowest levels across these variables. A strong positive correlation was observed between Asprosin and insulin resistance indicators such as HOMA-IR. Conclusions: Elevated serum Asprosin correlates with the presence and severity of diabetic retinopathy and aligns with dysregulated lipid and glycemic profiles. These findings support the potential of Asprosin as an early biomarker for DR risk and progression. Future longitudinal studies are necessary to determine its causal role and clinical applicability in diabetes-related retinal complications.
References
Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 Diabetes. The Lancet. 2022 Nov; 400(10365): 1803-20. doi: 10.1016/S0140-6736(22)01655-5. DOI: https://doi.org/10.1016/S0140-6736(22)01655-5
Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden Through 2045: Systematic Review and Meta-Analysis. Ophthalmology. 2021 Nov; 128(11): 1580-91. doi: 10.1016/j.ophtha.2021.04.027. DOI: https://doi.org/10.1016/j.ophtha.2021.04.027
Kim MS, Park SJ, Joo K, Woo SJ. Trends and Barriers in Diabetic Retinopathy Screening: Korea National Health and Nutritional Examination Survey 2016-2021. Journal of Korean Medical Science. 2024 Jul; 39(27): e203. doi: 10.3346/jkms.2024.39.e203. DOI: https://doi.org/10.3346/jkms.2024.39.e203
Antonetti DA, Silva PS, Stitt AW. Current Understanding of the Molecular and Cellular Pathology of Diabetic Retinopathy. Nature Reviews Endocrinology. 2021 Apr; 17(4): 195-206. doi: 10.1038/s41574-020-00451-4. DOI: https://doi.org/10.1038/s41574-020-00451-4
Ansari P, Tabasumma N, Snigdha NN, Siam NH, Panduru RV, Azam S, et al. Diabetic Retinopathy: An Overview on Mechanisms, Pathophysiology, and Pharmacotherapy. Diabetology. 2022 Feb; 3(1): 159-75.oi:10.3390/diabetology3010011. DOI: https://doi.org/10.3390/diabetology3010011
Rohilla M, Bansal S, Garg A, Dhiman S, Dhankhar S, Saini M, et al. Discussing Pathologic Mechanisms of Diabetic Retinopathy and Therapeutic Potentials of Curcumin and β-Glucogallin in the Management of Diabetic Retinopathy. Biomedicine and Pharmacotherapy. 2023 Dec; 169: 115881. doi: 10.1016/j.biopha.2023.115881. DOI: https://doi.org/10.1016/j.biopha.2023.115881
Tang H, Luo N, Zhang X, Huang J, Yang Q, Lin H, et al. Association Between Biological Aging and Diabetic Retinopathy. Scientific Reports. 2024 May; 14(1): 10123. doi: 10.1038/s41598-024-60913-x. DOI: https://doi.org/10.1038/s41598-024-60913-x
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 Apr; 165(3): 566-79. doi: 10.1016/j.cell.2016.02.063. DOI: https://doi.org/10.1016/j.cell.2016.02.063
Abed BA, Salman IN, Ghannawi LA. Review of Asprosin as a New Biomarker for the Diagnosis of Different Diseases. Journal of Thi-Qar Science. 2023; 10(2). doi: 10.32792/utq/utjsci/v10i2.1125. DOI: https://doi.org/10.32792/utq/utjsci/v10i2.1125
Shabir K, Brown JE, Afzal I, Gharanei S, Weickert MO, Barber TM, et al. Asprosin, a Novel Pleiotropic Adipokine Implicated in Fasting and Obesity-Related Cardio-Metabolic Disease: Comprehensive Review of Preclinical and Clinical Evidence. Cytokine and Growth Factor Reviews. 2021 Aug; 60: 120-32. doi: 10.1016/j.cytogfr.2021.05.002. DOI: https://doi.org/10.1016/j.cytogfr.2021.05.002
Seo H, Park SJ, Song M. Diabetic Retinopathy: Mechanisms, Current Therapies, and Emerging Strategies. Cells. 2025 Mar; 14(5): 376. doi: 10.3390/cells14050376. DOI: https://doi.org/10.3390/cells14050376
Farrag M, Ait Eldjoudi D, González-Rodríguez M, Cordero-Barreal A, Ruiz-Fernandez C, Capuozzo M, et al. Asprosin in Health and Disease: A New Glucose Sensor With Central and Peripheral Metabolic Effects. Frontiers in Endocrinology. 2023 Jan; 13: 1101091. doi: 10.3389/fendo.2022.1101091. DOI: https://doi.org/10.3389/fendo.2022.1101091
Li Y, Tian J, Hou T, Gu K, Yan Q, Sun S, et al. Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort. Diabetes Care. 2024 Mar; 47(3): 353-61. doi: 10.2337/dc23-0386. DOI: https://doi.org/10.2337/dc23-0386
Chandrasekaran P, Weiskirchen R. Diabetes Mellitus and Heart Disease. Metabolism Target Organ Damage. 2024 Apr; 4: 18. doi: 10.20517/mtod.2024.15. DOI: https://doi.org/10.20517/mtod.2024.15
Li Y, Mitchell W, Elze T, Zebardast N. Association Between Diabetes, Diabetic Retinopathy, and Glaucoma. Current Diabetes Reports. 2021 Oct; 21(10): 38. doi: 10.1007/s11892-021-01404-5. DOI: https://doi.org/10.1007/s11892-021-01404-5
Poshtchaman F, Dehnabi A, Poshtchaman Z, Birjandi B. HbA1C, Proliferative and Non-Proliferative Retinopathy in Diabetic Patients. Medicina Clinica Practica. 2023 Jul; 6(3): 100371. doi: 10.1016/j.mcpsp.2023.100371. DOI: https://doi.org/10.1016/j.mcpsp.2023.100371
Liang Y, Zhang X, Mei W, Li Y, Du Z, Wang Y, et al. Predicting Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus: Systematic Review, Meta-Analysis, and Prospective Validation Study. Journal of Global Health. 2024 Oct; 14: 04192. doi: 10.7189/jogh.14.04192. DOI: https://doi.org/10.7189/jogh.14.04192
Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TT, et al. Diabetic Retinopathy as the Leading Cause of Blindness and Early Predictor of Cascading Complications-Risks and Mitigation. Epma Journal. 2023 Mar; 14(1): 21-42. doi: 10.1007/s13167-023-00314-8. DOI: https://doi.org/10.1007/s13167-023-00314-8
Cui T, Lin D, Yu S, Zhao X, Lin Z, Zhao L, et al. Deep Learning Performance of Ultra-Widefield Fundus Imaging for Screening Retinal Lesions in Rural Locales. Journal of the American Medical Association Ophthalmology. 2023 Nov; 141(11): 1045-51. doi: 10.1001/jamaophthalmol.2023.4650. DOI: https://doi.org/10.1001/jamaophthalmol.2023.4650
Ma L, Wang Z, Sun L, Li M, Wu Q, Liu M, et al. Association Analysis Between Serum Asprosin and Metabolic Characteristics, Complications in Type 2 Diabetic Patients With Different Durations. Journal of Diabetes Investigation. 2024 Dec; 15(12): 1781-7. doi: 10.1111/jdi.14313. DOI: https://doi.org/10.1111/jdi.14313
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
